Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2369
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review ; volume:15 ; number:1 ; day:15 ; month:1 ; year:2014 ; pages:1-17 ; date:12.2014
BMC nephrology ; 15, Heft 1 (15.1.2014), 1-17, 12.2014
- Urheber
-
Huang, Yunyu
- Beteiligte Personen und Organisationen
-
Zhou, Qiyun
Haaijer-Ruskamp, Flora M.
Postma, Maarten J.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2369-15-15
- URN
-
urn:nbn:de:1111-201608132046
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huang, Yunyu
- Zhou, Qiyun
- Haaijer-Ruskamp, Flora M.
- Postma, Maarten J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
![Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?